These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 15548437)

  • 61. Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles.
    Kramer G; Schwarz S; Hägg M; Havelka AM; Linder S
    Br J Cancer; 2006 Jun; 94(11):1592-8. PubMed ID: 16685278
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Weekly administration of docetaxel and epirubicin as first-line treatment for hormone-refractory prostate carcinoma.
    Neri B; Molinara E; Pantaleo P; Rangan S; Crisci A; Della Melina A; Raugei A; Villari D; Nicitat G
    Oncol Res; 2009; 17(11-12):565-70. PubMed ID: 19806787
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Phase II study of vinorelbine with low dose prednisone in the treatment of hormone-refractory metastatic prostate cancer.
    Robles C; Furst AJ; Sriratana P; Lai S; Chua L; Donnelly E; Solomon J; Sundaram M; Feun L; Savaraj N
    Oncol Rep; 2003; 10(4):885-9. PubMed ID: 12792740
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Vinorelbine in androgen-independent metastatic prostatic carcinoma--a phase II study.
    Morant R; Hsu Schmitz SF; Bernhard J; Thürlimann B; Borner M; Wernli M; Egli F; Forrer P; Streit A; Jacky E; Hanselmann S; Bauer J; Hering F; Schmid HP
    Eur J Cancer; 2002 Aug; 38(12):1626-32. PubMed ID: 12142053
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Vinorelbine and prednisone in older cancer patients with hormone-refractory metastatic prostate cancer. A phase II study.
    Tralongo P; Bollina R; Aiello R; Di Mari A; Moruzzi G; Beretta G; Mauceri G; Conti G
    Tumori; 2003; 89(1):26-30. PubMed ID: 12729357
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Combination chemotherapy of docetaxel and UFT against hormone refractory prostate cancer].
    Shimasaki T; Miyazawa K; Moriyama M; Tanaka T; Sato I; Nakaya N; Nakajima H; Kubo A; Suzuki K; Motoo Y
    Hinyokika Kiyo; 2011 Mar; 57(3):163-6. PubMed ID: 21586891
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A phase II evaluation of oral tamoxifen and intermittent intravenous vinblastine in hormone-refractory adenocarcinoma of the prostate.
    Pienta KJ; Redman BG; Esper PS; Flaherty LE
    Am J Clin Oncol; 1996 Oct; 19(5):500-3. PubMed ID: 8823479
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Reinduction of hormone sensitivity to goserelin following chemotherapy with vinorelbine in castration-resistant prostate cancer.
    Grenader T; Goldberg A
    ScientificWorldJournal; 2010 Sep; 10():1814-7. PubMed ID: 20852824
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Chemotherapy for patients with hormone-refractory prostate cancer.
    Joly F; Tannock IF
    Ann Oncol; 2004 Nov; 15(11):1582-4. PubMed ID: 15520057
    [No Abstract]   [Full Text] [Related]  

  • 70. Assessment of hormone refractory prostate cancer.
    Newling D; Fosså SD; Andersson L; Abrahamsson PA; Aso Y; Eisenberger MA; Khoury S; Kozlowski JS; Kelly K; Scher H; Hartley-Asp B
    Urology; 1997 Apr; 49(4A Suppl):46-53. PubMed ID: 9111614
    [TBL] [Abstract][Full Text] [Related]  

  • 71. RNF7 knockdown inhibits prostate cancer tumorigenesis by inactivation of ERK1/2 pathway.
    Xiao Y; Jiang Y; Song H; Liang T; Li Y; Yan D; Fu Q; Li Z
    Sci Rep; 2017 Mar; 7():43683. PubMed ID: 28252001
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Update on options for treatment of metastatic castration-resistant prostate cancer.
    Vishnu P; Tan WW
    Onco Targets Ther; 2010 Jun; 3():39-51. PubMed ID: 20616956
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Colchitaxel, a coupled compound made from microtubule inhibitors colchicine and paclitaxel.
    Bombuwala K; Kinstle T; Popik V; Uppal SO; Olesen JB; Viña J; Heckman CA
    Beilstein J Org Chem; 2006 Jun; 2():13. PubMed ID: 16813651
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma.
    Gravis G; Bladou F; Salem N; Macquart-Moulin G; Serment G; Camerlo J; Genre D; Bardou VJ; Maraninchi D; Viens P
    Cancer; 2003 Oct; 98(8):1627-34. PubMed ID: 14534878
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study.
    Di Lorenzo G; Autorino R; Perdonà S; De Laurentiis M; D'Armiento M; Cancello G; Mirone V; Imbimbo C; Longo N; Altieri V; Tortora G; Figg WD; De Placido S
    Eur Urol; 2007 Oct; 52(4):1020-7. PubMed ID: 17360103
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer.
    Krainer M; Tomek S; Elandt K; Horak P; Albrecht W; Eisenmenger M; Höltl W; Schramek P; Stackl W; Zielinski C; Reibenwein J
    J Urol; 2007 Jun; 177(6):2141-5; discussion 2145. PubMed ID: 17509302
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
    Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
    Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.
    Nelius T; Reiher F; Lindenmeir T; Klatte T; Rau O; Burandt J; Filleur S; Allhoff EP
    Onkologie; 2005 Nov; 28(11):573-8. PubMed ID: 16249643
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer.
    Di Lorenzo G; Pizza C; Autorino R; De Laurentiis M; Marano O; D'Alessio A; Cancello G; Altieri V; Tortora G; Perdonà S; Bianco AR; De Placido S
    Eur Urol; 2004 Dec; 46(6):712-6. PubMed ID: 15548437
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.